Advertisement

Topics

Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

05:11 EST 9 Nov 2017 | SCRIP

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech...

      

Related Stories

 

Original Article: Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

NEXT ARTICLE

More From BioPortfolio on "Ono Bulks Up MAb R&D With Second Swiss Biotech Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...